Mendelian randomization study on the causal effects of omega-3 fatty acids on rheumatoid arthritis

2022 ◽  
Author(s):  
Gaizhi Zhu ◽  
Shan Zhou ◽  
Yaqi Xu ◽  
Ran Gao ◽  
Huan Li ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Fatty Acids ◽  
Mendelian Randomization ◽  
Causal Effects ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 223
Author(s):  
Kassandra Lanchais ◽  
Frederic Capel ◽  
Anne Tournadre
Keyword(s):  
Rheumatoid Arthritis ◽  
Insulin Resistance ◽  
Fatty Acids ◽  
Density Lipoprotein ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Cvd Risk ◽  
Cardiometabolic Diseases ◽  
Increased Risk ◽  
Muscle Health

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by a high prevalence of death due to cardiometabolic diseases. As observed during the aging process, several comorbidities, such as cardiovascular disorders (CVD), insulin resistance, metabolic syndrome and sarcopenia, are frequently associated to RA. These abnormalities could be closely linked to alterations in lipid metabolism. Indeed, RA patients exhibit a lipid paradox, defined by reduced levels of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol whereas the CVD risk is increased. Moreover, the accumulation of toxic lipid mediators (i.e., lipotoxicity) in skeletal muscles can induce mitochondrial dysfunctions and insulin resistance, which are both crucial determinants of CVD and sarcopenia. The prevention or reversion of these biological perturbations in RA patients could contribute to the maintenance of muscle health and thus be protective against the increased risk for cardiometabolic diseases, dysmobility and mortality. Yet, several studies have shown that omega 3 fatty acids (FA) could prevent the development of RA, improve muscle metabolism and limit muscle atrophy in obese and insulin-resistant subjects. Thereby, dietary supplementation with omega 3 FA should be a promising strategy to counteract muscle lipotoxicity and for the prevention of comorbidities in RA patients.

scholarly journals The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial

2015 ◽  
Vol 8 (7) ◽  
pp. 18 ◽  
Author(s):  
Elham Rajaei ◽  
Karim Mowla ◽  
Ali Ghorbani ◽  
Sara Bahadoram ◽  
Mohammad Bahadoram ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Fatty Acids ◽  
Disease Activity ◽  
Active Rheumatoid Arthritis ◽  
Controlled Study ◽  
Unknown Etiology ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Weight Changes ◽  
Double Blind

<p><strong>BACKGROUND:</strong> Rheumatoid arthritis is a symmetric peripheral polyarthritis of unknown etiology that, untreated or if unresponsive the therapy, typically leads to deformity and destruction of joints due to erosion of cartilage and bone. Omega-3 fatty acids have been shown to reduce morning stiffness, the number of tender joints and swollen joints in patients with rheumatoid arthritis. This study is designed for evaluation of omega-3 effects on disease activity and remission of rheumatoid arthritis in DMARDs treated patients and on weight changes and reduction of analgesic drugs consumption versus placebo.</p><p><strong>METHODS:</strong> Sixty patients with active rheumatoid arthritis (49 female and 11 male) underwent rheumatologist examination and disease activity score were calculated. Then patients were enrolled in this 12 week, double blind, randomized, placebo- controlled study. The patients in both groups continued their pre study standard treatment. The patients were visited every 4 weeks, 4 times and data were recorded.</p><p><strong>RESULTS:</strong> Significant improvement in the patient's global evaluation and in the physician's assessment of disease was observed in those taking omega-3. The proportions of patients who improved and of those who were able to reduce their concomitant analgesic medication were significantly greater with omega-3 consumption. There were no weight changes.</p><p><strong>CONCLUSION:</strong> Daily supplementation with omega-3 results has significant clinical benefit and may reduce the need for concomitant analgesic consumption without weight changes.</p>

scholarly journals An Overview of Analeptic Applications of Omega-3 Fatty Acids

2021 ◽  
pp. 95-118
Author(s):  
Bharat Kwatra ◽  
Harsimran Kaur ◽  
Joydip Majumdar ◽  
Mahek Shah ◽  
Mansi Upadhyaya ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Fatty Acids ◽  
Cardiovascular Health ◽  
The Body ◽  
Omega 3 Fatty Acids ◽  
Skin Disorders ◽  
Omega 3 ◽  
Pufa Ratio ◽  
Omega 6 ◽  
Anti Inflammatory

This article is an examination of the Analeptic Applications of Omega-3. The scientific development and subsequent clinical applications of Omega-3 in Healthcare continue to influence researchers all over the globe today. This article examines the research done and published by researchers and scientists. Consideration of current trends and data in scientific queries and demonstrates further aspects of the applications of Omega-3 on various health backgrounds, including. Cardiovascular Health: The study addresses the comparison of Omega-3 and Omega-6 in cardiovascular diseases. Higher intake of dietary Omega-3 helps activation, inhibition, and alteration of metabolic and signaling pathways which is associated with better cardiovascular health, while Omega-6 decreases the risk of coronary heart diseases and cardiovascular disease mortality. Immunology: Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been found to show an anti-inflammatory effect in the body by downregulating the activation of various immune cells. They regulate immunological functions via eicosanoids and resolvins which are anti-inflammatory. External supplementation can reduce chronic and acute inflammation as well as reduce the chances of graft rejection. The regulatory effect is shown by modifying gene expression and/or signal transduction in human cells. They are also involved in altering the membrane composition of Fatty Acids(FA) and as a result, they affect the lipid raft structure and also membrane trafficking. Joint Health: The study shows the effects of omega-3 and other fatty acid consumption in Rheumatoid Arthritis(RA), bone marrow lesions, and knee cartilage lesions. It notes the interrelations between synovitis, plasma levels of Omega-3 and Omega-6 PUFAs in OsteoArthritis (OA) patients along with risk factors for OA, which could help consider liable treatments for improvement of OA. The study highlights the importance of the Omega-6:Omega-3 PUFA ratio and clinical and functional outcome measures which can help us in better understanding the role of PUFAs and possible treatments for people with knee osteoarthritis while showing the effect of Omega-3 fatty acids on muscle health in RA. Skin Disorders: Fish oils rich in PUFAs are reported to improve several inflammatory disorders, including rheumatoid arthritis and psoriasis. They have also been broadly reported as a potential supplement to ameliorate the severity of some skin disorders such as photoaging, skin cancer, allergy, dermatitis, cutaneous wounds, and melanogenesis. The significance of omega-3 in skin structure was proved by describing a syndrome caused by stringent fat reduction in the diet that leads to erythema with scaling, hair loss, itching, and increased water loss.

scholarly journals Increased Levels of Omega-3 Fatty Acids and DHA Are Linked to Pain Reduction in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors

Nutrients ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 3050
Author(s):  
Ching-Kun Chang ◽  
Po-Ku Chen ◽  
Chia-Ching Chen ◽  
Shih-Hsin Chang ◽  
Chu-Huang Chen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Fatty Acids ◽  
Kinase Inhibitors ◽  
Serum Levels ◽  
Pain Reduction ◽  
Janus Kinase ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Janus Kinase Inhibitors ◽  
Lipid Metabolites

Although Janus kinase inhibitors (JAKi) could reduce patient-reported pain in rheumatoid arthritis (RA), their mechanism remains unclear. Therefore, we examined lipid metabolites change in JAKi-treated patients and evaluate their association with pain reduction. We used 1H-NMR-based lipid/metabolomics to determine serum levels of lipid metabolites at baseline and week 24 of treatment. Serum levels of significant lipid metabolites were replicated by ELISA in 24 JAKi-treated and 12 tocilizumab-treated patients. Pain was evaluated with patients’ assessment on a 0-100mm VAS, and disease activity assessed using DAS28. JAKi or tocilizumab therapy significantly reduced disease activity. Acceptable pain (VAS pain ≤20) at week 24 was observed in 66.7% of JAKi-treated patients, and pain decrement was greater than tocilizumab-treated patients (ΔVAS pain 70.0 vs. 52.5, p = 0.0595). Levels of omega-3 fatty acids and docosahexaenoic acid (DHA) were increased in JAKi-treated patients (median 0.55 mmol/L versus 0.71 mmol/L, p = 0.0005; 0.29 mmol/L versus 0.35 mmol/L, p = 0.0004; respectively), which were not observed in tocilizumab-treated patients. ELISA results showed increased DHA levels in JAKi-treated patients with acceptable pain (44.30 µg/mL versus 45.61 µg/mL, p = 0.028). A significant association of pain decrement with DHA change, not with DAS28 change, was seen in JAKi-treated patients. The pain reduction effect of JAKi probably links to increased levels of omega-3 fatty acids and DHA.

scholarly journals Role of omega-3 fatty acid supplementation with indomethacin in suppression of disease activity in rheumatoid arthritis

2009 ◽  
Vol 35 (2) ◽  
pp. 63-68 ◽  
Author(s):  
Ashoke Bijoy Das Gupta ◽  
A.K.M. Mosharrof Hossain ◽  
Md. Hilalul Islam ◽  
Sudhangshu Ranjan Dey ◽  
Md. Abdul Latif Khan
Keyword(s):  
Rheumatoid Arthritis ◽  
Fatty Acids ◽  
Disease Activity ◽  
Morning Stiffness ◽  
Treated Group ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Omega 3 Fatty Acid

 A study was conducted to see the diseases activity suppression role of omega-3 fatty acids with indomethacin in patients with rheumatoid arthritis. One group received indomethacin (75 mg) only daily while another group received indomethacin (75 mg) along with omega-3 fatty acids (3 g) daily for 12 weeks. The main outcome measures were DAS 2-28 joints score, number of swollen joints, number of tender joints, duration of morning stiffness, grip strength, pain VAS, patients global VAS, erythrocyte sedimentation rate and C-reactive protein. In terms of outcome both the groups experienced a modest improvement in disease activity after 12 weeks of treatment. However, compared to indomethacin–treated group, omega-3 plus indomethacin–treated group achieved a better improvement in terms of reducing disease activity. Physical functioning, physical role, bodily pain, general health, vitality, social functioning, grip strength, duration of morning stiffness improved significantly better in the combination group compared to indomethacin only group. The safety measures included liver and kidney function tests done didn’t differ between the study groups. This study suggests that omega-3 fatty acid supplementation with indomethacin might ameliorate disease activity and be non-steroidal anti-inflammatory drugs (NSAIDs) sparing in rheumatoid arthritis.Keywords: Rheumatoid arthritis; Indomethacin; Omega-3 fatty acidOnline: 25 August 2009DOI: 10.3329/bmrcb.v35i2.3020Bangladesh Med Res Counc Bull 2009; 35: 63-68  

Sign in / Sign up

Export Citation Format

Share Document